• CSPC Pharmaceutical Group adopted the 2026 Share Award Scheme, a restricted share award plan to be satisfied through on-market purchases of existing shares held by a trustee until vesting.
• The total number of shares that may be purchased under the 2026 Share Award Scheme is capped at 3% of issued shares as of the adoption date, with 11.5 billion shares in issue at that time.
• Grants to any selected participant are limited to 0.5% of issued shares as of the adoption date.
• The 2018 Share Award Scheme remains in force until 19 August 2028, with 64.0 million shares available for future grants and 53,318,500 outstanding share awards granted but unvested.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12067391), on March 25, 2026, and is solely responsible for the information contained therein.